Biosceptre’s current product development programs address large market opportunities comprising the following diagnostics and immuno-therapeutics for cancer:
Cancer Clinical Diagnostics Market
Clinical diagnostics sales exceeded $28.5 billion in 2004 and are expected to grow to $39 billion by 2008. Cancer diagnostics currently account for $25.8 billion, the majority of that market.
More than 170 million cancer screening and diagnostic procedures were performed in the US in 2004, representing $9.8 billion or 38% of the $25.8 billion worldwide cancer diagnostic market.
Europe, Japan and the rest of the world accounted for $9.3 billion, $2.6 billion and $4.1 billion respectively.
Biosceptre’s target applications for prostate and colon / rectal cancer alone represent approximately $1.9 billion.
In Vitro Diagnostics for Cancer
In 2004, worldwide sales of in vitro cancer diagnostics were estimated at $4 billion of which sales of IHC-based tests were estimated at $600 million. Worldwide sales of in vitro tests for cancer are expected to grow annually by 13%, reaching $7.4 billion by 2009 according to a recently released study by Kalorama Information.
In Vivo Imaging
Molecular imaging will have a central role in aiding physicians to identify specific sites of cancer growth and metastases and monitoring treatment. Currently, molecular imaging agents using various targeting media (such as monoclonal antibodies) and conventional imaging modalities are in development and are expected to address a large unmet need for highly targeted diagnosis and therapeutic management. This market potential is estimated to be approximately $1 billion.
Cancer Therapeutics Market
The global market for cancer therapies surpassed sales of US$42 billion in 2004 with future growth estimated to exceed 25%, according to a study released by Kalorama Information. Immuno-therapeutic approaches to cancer, including monoclonal antibodies, cancer vaccines, interleukins, and a host of other biotechnology inspired therapeutics, accounted for 18% of the global market in 2004 and may approach one-third of all cancer therapeutic revenues by 2009, according to the study.
Topical Skin Cancer Therapeutic
Basal cell carcinoma, a skin cancer, is the most common form of all human cancers with approximately 1,000,000 new cases every year in the U.S and 400,000 in Australia. The overall topical skin cancer therapeutic market potential is estimated at approximately US$5 billion.
The global market for cancer therapies surpassed sales of $42 billion in 2004 with future growth estimated to exceed 25% according to a study released by Kalorama Information.
Immunotherapeutic approaches to cancer, including monoclonal antibodies, cancer vaccines, interleukins and a host of other biotechnology inspired therapeutics accounted for 18% of the global market in 2004 and may approach one-third of all cancer therapeutic revenues by 2009, according to the study.